Azitra, Inc. AZTR

AZTR Company Overview

Azitra, Inc. is a clinical-stage biotechnology company focused on precision dermatology and engineered live biotherapeutic products. The company develops therapies derived from the human microbiome, primarily targeting dermatological and rare disease indications. Azitra operates within the biotechnology, dermatology therapeutics, and microbiome-based medicine sectors, with research centered on engineering commensal bacteria to deliver therapeutic proteins and modulate skin disease pathways.

The company’s primary programs have focused on genetically engineered strains of Staphylococcus epidermidis and related microbial platforms intended for conditions such as Netherton syndrome and other inflammatory or genetic skin disorders. Azitra’s strategic positioning is based on combining synthetic biology, microbiome science, and dermatology-focused drug development into a differentiated platform targeting diseases with limited treatment options. The company traces its origins to microbiome research developed at Yale University and has evolved from an early-stage research venture into a publicly traded biotechnology company listed on the NYSE American under the ticker AZTR.